Financial Performance - Sylvamo reported a 7% sales volume growth quarter-over-quarter in Q3 2025, with net sales reaching $846 million compared to $794 million in Q2 2025[6][21]. - Year-to-date net income for 2025 was $57 million, or $1.41 per diluted share, with adjusted EBITDA of $151 million, reflecting an 18% margin[6][21]. - Net sales for the three months ended September 30, 2025, were $846 million, a decrease of 12.3% compared to $965 million for the same period in 2024[35]. - Net income for the three months ended September 30, 2025, was $57 million, down 40% from $95 million in the same period last year[35]. - Adjusted EBITDA for the three months ended September 30, 2025, was $151 million, representing an adjusted EBITDA margin of 18%[52]. - Operating profit for North America segment was $84 million for the three months ended September 30, 2025, compared to $98 million in the same period of 2024[47]. - Latin America segment reported net sales of $228 million for the three months ended September 30, 2025, down from $247 million in the same period last year[46]. - Adjusted EBITDA for North America was $101 million for the three months ended September 30, 2025, down from $113 million in the same period of 2024, reflecting a decrease of 10.6%[53]. - Total Business Segment Net Sales decreased to $862 million for the three months ended September 30, 2025, compared to $973 million in the same period of 2024, a decline of 11.4%[53]. - Adjusted EBITDA Margin for Europe was negative 6% for the three months ended September 30, 2025, compared to a positive 6% in the same period of 2024[53]. - Net income for the nine months ended September 30, 2025, was $99 million, a decrease of 55% from $221 million in the same period of 2024[57]. Shareholder Returns - The company returned a total of $60 million to shareholders in Q3 2025, consisting of $42 million in share repurchases and $18 million in dividends[3][6]. - The company has authorized a new $150 million share repurchase program, emphasizing its commitment to disciplined capital allocation[8]. Cost and Expense Management - The company is focused on strategic initiatives to improve margins and reduce costs, including optimizing product and customer mix in response to changing market conditions[10][12]. - Total costs and expenses for the three months ended September 30, 2025, were $758 million, compared to $833 million for the same period in 2024[35]. - The company incurred a net special items expense of $1 million for the three months ended September 30, 2025[44]. Tax and Income Provisions - The effective tax rate for Q3 2025 was reported at 35%, an increase from 25% in Q2 2025, attributed to the mix of earnings across regions[26]. - Income tax provision for the three months ended September 30, 2025, was $31 million, compared to $37 million for the same period in 2024[52]. Cash Flow and Assets - Cash provided by operating activities for the nine months ended September 30, 2025, was $174 million, down from $305 million in the same period of 2024, a decrease of 43%[57]. - Free Cash Flow for the nine months ended September 30, 2025, was $6 million, significantly lower than $148 million in the same period of 2024[59]. - Cash and temporary investments decreased to $94 million as of September 30, 2025, from $205 million at the beginning of the period, a decline of 54%[56]. - Total assets increased to $2,703 million as of September 30, 2025, compared to $2,604 million as of December 31, 2024, an increase of 3.8%[55]. - The company reported a total equity of $977 million as of September 30, 2025, up from $847 million as of December 31, 2024, an increase of 15.4%[55]. Market Outlook - The fourth quarter outlook projects a decrease in price and mix by $20 million to $25 million, while volume is expected to improve by $15 million to $20 million[6]. - In Europe, uncoated freesheet demand decreased by 5% year-over-year through September, while supply fell by 7%, indicating challenging industry conditions[13]. Future Projections - The company plans to achieve an Adjusted EBITDA of $115 to $130 million for the fourth quarter of 2025[62].

Portfolio Overview - As of September 30, 2025, the company's Portfolio totaled approximately $7.5 billion, including $3.7 billion in Behind-the-Meter (BTM) assets, $2.8 billion in Grid-Connected (GC) assets, and $1.0 billion in Fuels, Transport, and Nature (FTN) assets[208]. - The company's pipeline of potential new opportunities as of September 30, 2025, consisted of more than $6.0 billion, with approximately 39% related to BTM assets, 38% to GC assets, and 18% to FTN assets[203]. - Approximately 53% of the Portfolio consisted of equity method investments in renewable energy-related projects, while 37% consisted of fixed-rate receivables and debt securities[208]. - The average size of transactions in the Portfolio was approximately $11 million, with a weighted average remaining life of about 16 years[208]. - The GAAP-based Portfolio increased to $7.542 billion as of September 30, 2025, compared to $6.594 billion as of December 31, 2024, reflecting a growth of 14.4%[235]. Financial Performance - The company completed approximately $649 million and $1.5 billion of transactions during the three and nine months ended September 30, 2025, respectively, compared to approximately $396 million and $1.2 billion during the same periods in 2024[200]. - Total revenue for Q3 2025 reached $103.064 million, a 26% increase from $81.965 million in Q3 2024[215]. - Net income for Q3 2025 was $84.906 million, a significant increase of $104.082 million compared to a net loss of $19.176 million in Q3 2024[216]. - For the nine months ended September 30, 2025, total revenue was $285.690 million, a slight increase of 1% from $282.298 million in the same period of 2024[217]. - Net income for the nine months ended September 30, 2025, was $242.886 million, an increase of $110.570 million or 84% compared to $132.316 million in 2024[217]. Income and Expenses - Interest and rental income for Q3 2025 increased to $68.976 million, up 8% from $64.151 million in Q3 2024[215]. - Interest expense rose to $71.481 million in Q3 2025, reflecting a 20% increase from $59.401 million in Q3 2024[215]. - The average cost of debt for Q3 2025 was 5.9%, compared to 5.6% in Q3 2024[215]. - Adjusted Earnings for Q3 2025 were $102.5 million, or $0.80 per share, up from $62.6 million, or $0.52 per share in Q3 2024[228]. - The company reported a return of capital of $25 million in Q3 2025, compared to $6 million in Q3 2024[226]. Cash Flow and Liquidity - Cash collected in Q3 2025 was $93 million, significantly higher than $32 million in Q3 2024[226]. - The total cash collected for the nine months ended September 30, 2025, was $187 million, compared to $67 million in the same period of 2024[226]. - Total liquidity available as of September 30, 2025, was $1.136 billion, consisting of $302 million in unrestricted cash and $804 million in unused capacity under the unsecured revolving credit facility[250]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $759 million, significantly higher than the $(89) million reported for the same period in 2024[271]. - Cash used in investing activities decreased by $565 million compared to the same period in 2024, with increased investments in equity method investments and receivables[270]. Debt and Financing - The company has a strategic partnership with KKR for joint investments in eligible projects, enhancing its investment capabilities[202]. - The company entered into a delayed-draw term loan facility of up to $250 million, available from March 16, 2026, to June 15, 2026, with a maturity date of June 15, 2028[252]. - As of September 30, 2025, the company's long-term recourse debt obligations totaled $5.189 billion, with a debt-to-equity ratio of approximately 1.9 to 1, below the board-approved limit of 2.5 to 1[260][261]. - The percentage of fixed-rate debt was approximately 88% as of September 30, 2025, within the targeted range of 75% to 100%[261]. - The company plans to continue issuing debt, which may be secured or unsecured, and may also issue additional equity to finance its business[258]. Risk Management - The company anticipates that its primary market risks will relate to credit quality, market interest rates, liquidity of assets, and commodity prices[278]. - The company actively manages credit risk through thorough due diligence, strong structural protections, and continuous portfolio monitoring[290]. - The company employs various interest rate management techniques to mitigate risks, including matching debt maturities with asset maturities and using interest rate swaps[282]. - Environmental risks are integral to the company's investment parameters, and ongoing asset management includes monitoring these risks[290]. - Changes in discount rates will impact the fair value of certain assets recorded at fair value in the financial statements[285].

Revenue Performance - Total revenues for the three months ended September 30, 2025, decreased by $34.1 million, or 6.2%, to $511.9 million compared to $545.9 million in the same period of 2024[126]. - Total revenues for the nine months ended September 30, 2025 decreased by $51.9 million, or 3.9%, to $1,289.0 million compared to $1,340.9 million for the same period in 2024[135]. - Admissions revenue for the nine months ended September 30, 2025 decreased by $46.3 million, or 6.4%, to $680.5 million compared to $726.8 million for the same period in 2024[136]. Attendance and Admissions - Admissions revenue decreased by $28.3 million, or 9.5%, to $268.7 million, primarily due to a decrease in admission per capita and attendance, which fell by approximately 240,000 guests, or 3.4%[127]. - Attendance levels are influenced by factors such as affordability, new attractions, competitive offerings, and global economic conditions[118]. - Total attendance for the first nine months of 2025 decreased by approximately 252 thousand guests, or 1.5%, compared to the first nine months of 2024[136]. Operating Expenses - Operating expenses increased by $7.1 million, or 3.4%, to $214.4 million, primarily due to higher labor-related costs and increased non-cash self-insurance adjustments[130]. - Selling, general and administrative expenses rose by $5.3 million, or 9.6%, to $60.7 million, driven by increased third-party consulting costs and legal fees[131]. - Inflation has significantly impacted the company's operations, affecting costs related to food, merchandise, labor, and utilities[171]. Net Income and Profitability - Net income for the three months ended September 30, 2025, was $89.3 million, a decrease of $30.4 million, or 25.4%, compared to $119.7 million in the prior year[126]. - Net income for the nine months ended September 30, 2025 decreased by $46.3 million, or 23.2%, to $153.3 million compared to $199.6 million for the same period in 2024[135]. - Operating income for the nine months ended September 30, 2025 decreased by $78.5 million, or 20.3%, to $309.0 million compared to $387.5 million for the same period in 2024[135]. Cash Flow and Financing - Net cash provided by operating activities was $301.7 million during the nine months ended September 30, 2025, down from $367.7 million during the same period in 2024[150]. - Net cash used in financing activities for the nine months ended September 30, 2025, was $16.3 million for share repurchases and $11.6 million for long-term debt repayments, compared to $445.3 million and $238.2 million respectively in 2024[155][158]. - As of September 30, 2025, the company had $1.527 billion in Term B-3 Loans maturing on December 4, 2031, and a $700 million Revolving Credit Facility with approximately $689.1 million available for borrowing[158]. Cost Management and Strategic Initiatives - The company has identified meaningful cost savings opportunities, including technology initiatives, to improve operating margins[120]. - The company incurred $4.4 million in business optimization costs for the three months ended September 30, 2025, reflecting ongoing strategic initiatives[166]. Debt and Compliance - Approximately $1.5 billion of the company's long-term debt is variable-rate debt, with a hypothetical 100 bps increase in Term SOFR potentially increasing annual interest expense by approximately $22.3 million[173][174]. - The company was in compliance with all covenants in the credit agreement governing the Senior Secured Credit Facilities and the indentures governing its Senior Notes as of September 30, 2025[160]. Depreciation and Amortization - Depreciation and amortization expense for the nine months ended September 30, 2025 increased by $8.3 million, or 6.9%, to $129.4 million compared to $121.0 million for the same period in 2024[141]. In-Park Spending - Food, merchandise, and other revenue decreased by $5.7 million, or 2.3%, to $243.2 million, despite a 1.1% increase in in-park per capita spending, which rose to $35.82[128]. - In-park per capita spending increased by 0.6% to $37.07 for the nine months ended September 30, 2025 compared to $36.85 for the same period in 2024[137]. EBITDA Metrics - Adjusted EBITDA for the nine months ended September 30, 2025, was $489.98 million, compared to $555.72 million in 2024, reflecting a decrease of approximately 11.7%[166]. - Covenant Adjusted EBITDA for the last twelve months ended September 30, 2025, was $654.73 million, which includes estimated cost savings adjustments[166]. Seasonal Trends - The theme park industry is seasonal, with approximately two-thirds of attendance and revenues generated in the second and third quarters[123]. Contractual Obligations - There were no material changes to the company's contractual obligations as of September 30, 2025, compared to previous disclosures[167].

Revenue Performance - Total revenues for the three months ended September 30, 2025, decreased by $34.1 million, or 6.2%, to $511.9 million compared to $545.9 million in the same period of 2024[126]. - Admissions revenue decreased by $28.3 million, or 9.5%, to $268.7 million, primarily due to a decrease in admission per capita and attendance, which fell by approximately 240 thousand guests, or 3.4%[127]. - Food, merchandise, and other revenue decreased by $5.7 million, or 2.3%, to $243.2 million, despite an increase in in-park per capita spending, which rose by 1.1% to $35.82[128]. - Net revenues for the nine months ended September 30, 2025 decreased by $51.9 million, or 3.9%, to $1,289.0 million compared to $1,340.9 million for the same period in 2024[135]. - Admissions revenue for the nine months ended September 30, 2025 decreased by $46.3 million, or 6.4%, to $680.5 million compared to $726.8 million for the same period in 2024[136]. - Total attendance for the first nine months of 2025 decreased by approximately 252 thousand guests, or 1.5%, compared to the same period in 2024[136]. Operating Expenses - Operating expenses increased by $7.1 million, or 3.4%, to $214.4 million, primarily due to increased labor-related costs and non-cash self-insurance adjustments[130]. - Selling, general and administrative expenses increased by $5.3 million, or 9.6%, to $60.7 million, driven by higher third-party consulting costs and legal fees[131]. - Depreciation and amortization expense for the nine months ended September 30, 2025 increased by $8.3 million, or 6.9%, to $129.4 million compared to $121.0 million for the same period in 2024[141]. Net Income - Net income for the three months ended September 30, 2025, was $89.3 million, a decrease of $30.4 million, or 25.4%, compared to $119.7 million in the prior year[126]. - Net income for the nine months ended September 30, 2025 was $153.3 million, a decrease of $46.3 million, or 23.2%, compared to $199.6 million for the same period in 2024[135]. - The company reported a net income of $89.3 million for the three months ended September 30, 2025, down from $119.7 million in the same period of 2024[166]. Cash Flow and Financing - Net cash provided by operating activities was $301.7 million during the nine months ended September 30, 2025, down from $367.7 million during the same period in 2024[150]. - Net cash used in financing activities for the nine months ended September 30, 2025, was $16.3 million for share repurchases and $11.6 million for long-term debt repayments, compared to $445.3 million and $238.2 million respectively in the same period of 2024[155][158]. - As of September 30, 2025, the company had $1.527 billion in Term B-3 Loans maturing on December 4, 2031, and a $700 million Revolving Credit Facility with approximately $689.1 million available for borrowing[158]. Debt and Interest - Interest expense for the nine months ended September 30, 2025 decreased by $16.3 million, or 13.8%, to $101.6 million compared to $117.8 million for the same period in 2024[142]. - Approximately $1.5 billion of the company's long-term debt is variable-rate debt, with a hypothetical 100 bps increase in Term SOFR potentially increasing annual interest expense by approximately $22.3 million[174]. - The company was in compliance with all covenants in the credit agreement governing the Senior Secured Credit Facilities and the indentures governing its Senior Notes as of September 30, 2025[160]. Strategic Initiatives and Risks - The company has identified meaningful cost savings opportunities, including technology initiatives, to improve operating margins[120]. - Inflation and interest rate fluctuations are significant risks affecting the company's operations and financial performance[171][172]. - The company incurred $4.4 million in business optimization costs for the three months ended September 30, 2025, reflecting ongoing strategic initiatives[166]. - Attendance levels are influenced by factors such as affordability, new attractions, competitive offerings, and global economic conditions[118]. - The theme park industry is seasonal, with approximately two-thirds of attendance and revenues generated in the second and third quarters[123]. Adjusted Metrics - Adjusted EBITDA for the nine months ended September 30, 2025, was $489.98 million, compared to $555.72 million for the same period in 2024, reflecting a decrease of approximately 11.8%[166]. - Covenant Adjusted EBITDA for the last twelve months ended September 30, 2025, was $654.73 million, which includes estimated cost savings adjustments[166].

Exhibit 99.1 Essent Group Ltd. Announces Third Quarter 2025 Results and Declares Quarterly Dividend HAMILTON, Bermuda, November 7, 2025--Essent Group Ltd. (NYSE: ESNT) today reported net income for the quarter ended September 30, 2025 of $164.2 million or $1.67 per diluted share, compared to $176.2 million or $1.65 per diluted share for the quarter ended September 30, 2024. Essent also announced today that its Board of Directors has declared a quarterly cash dividend of $0.31 per common share. The dividend ...

Revenue Growth - Revenue increased by $12.3 million, or 17%, from $71.7 million in Q3 2024 to $84.1 million in Q3 2025[145]. - Revenue from laboratory services reached $83.9 million in Q3 2025, up 17% from $71.7 million in Q3 2024, driven by increases in precision diagnostics, anatomic pathology, and BioPharma services[145][146]. - Precision diagnostics revenue grew by $7.2 million, or 16%, in Q3 2025 compared to Q3 2024, attributed to growth in reproductive health services[145][146][147]. - Total revenue for the nine months ended September 30, 2025, was $239.3 million, a 16% increase from $207.3 million in the same period of 2024[146]. - BioPharma services revenue surged by 83% in Q3 2025 compared to Q3 2024, reflecting the timing of service projects[145][147]. - Revenue from non-U.S. sources increased by $0.4 million, or 7%, from $6.0 million in Q3 2024 to $6.5 million in Q3 2025[152]. Profitability and Loss - Operating loss improved to $(15.4) million in Q3 2025, a 10% reduction from $(17.1) million in Q3 2024[144]. - Net loss attributable to Fulgent decreased by $8.0 million, or 55%, from $(14.6) million in Q3 2024 to $(6.6) million in Q3 2025[144]. - Gross profit increased by $8.7 million, or 33%, from $26.8 million in Q3 2024 to $35.5 million in Q3 2025, with gross margin improving from 37% to 42%[156]. Expenses - Consolidated cost of revenue increased by $3.6 million, or 8%, from $45.0 million in Q3 2024 to $48.6 million in Q3 2025, with cost of revenue as a percentage of revenue rising from 58% to 63%[153][155]. - Research and development expenses for the therapeutic development segment increased by $2.0 million, or 41%, from $4.8 million in Q3 2024 to $6.8 million in Q3 2025[161]. - Selling and marketing expenses increased by $2.5 million, or 28%, from $9.1 million in Q3 2024 to $11.6 million in Q3 2025[165]. - General and administrative expenses increased by $2.4 million, or 11%, from $21.0 million in Q3 2024 to $23.3 million in Q3 2025[167]. Cash Flow and Financial Position - Cash, cash equivalents, restricted cash, and marketable securities totaled $787.7 million as of September 30, 2025, down from $828.6 million at the end of 2024[175]. - Cash used in operating activities for the nine months ended September 30, 2025, was $23.5 million, compared to $4.0 million for the same period in 2024, primarily due to the purchase of Investment Tax Credits for $31.7 million[181]. - Cash provided by investing activities for the nine months ended September 30, 2025, was $100.2 million, mainly from $132.9 million in maturities of marketable securities and $3.8 million from the acquisition of ANP[183]. - Cash used in financing activities for the nine months ended September 30, 2025, was $14.3 million, primarily related to $10.9 million for the repurchase of common stock[185]. - As of September 30, 2025, approximately $139.6 million remained available for future repurchases of common stock under the stock repurchase program authorized in March 2022[188]. - Cash used in operating activities increased significantly due to fluctuations in cash receipts and payments, influenced by demand for tests and product mix[181]. - The company did not need to draw on any credit facilities due to a strong cash position as of September 30, 2025[187]. Future Expectations - The company expects approximately $106.7 million in refunds from the IRS related to tax credits, anticipated to be issued before the end of 2025[140]. - The company expects research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other preclinical studies[164]. - The company expects to incur more operating expenses in the coming quarters due to planned clinical trials for FID-007 and FID-022, impacting cash flow[181]. - The company may seek additional capital through securities offerings or collaborations, which could lead to dilution for existing stockholders[178]. - The company may incur substantial costs in pursuing future capital, including investment banking and legal fees, which could impact growth plans[179]. Revenue Concentration Risks - A single customer contributed $19.2 million, or 23%, of total revenue in Q3 2025, highlighting revenue concentration risks[149]. - The company is focusing on increasing its customer base to mitigate revenue concentration risks[149]. Tax and Interest - Interest income was $7.9 million and $24.0 million for Q3 and the nine months ended September 30, 2025, respectively[170]. - The effective tax rate was 9% and 7% for Q3 and the nine months ended September 30, 2025, compared to 21% and 14% for the same periods in 2024[171].

Exhibit 99.1 THE WENDY'S COMPANY REPORTS THIRD QUARTER 2025 RESULTS Dublin, Ohio (November 7, 2025) - The Wendy's Company (Nasdaq: WEN) today reported unaudited results for the third quarter ended September 28, 2025. "Third quarter results were in line with our expectations, reflecting continued strength in our international business with 8.6% systemwide sales growth, the addition of 54 new restaurants globally and adjusted EBITDA growth," said Ken Cook, Interim CEO. "In the U.S. our actions to drive operat ...

Exhibit 99.1 Hain Celestial Reports Fiscal First Quarter 2026 Financial Results HOBOKEN, N.J., November 7, 2025 — The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal first quarter ended September 30, 2025. "First quarter results met our expectations on the top- and bottom-line. During the quarter, organic net sales trends demonstrated sequential ...

Acquisitions and Brand Development - RYTHM's acquisition of the Señorita brand in November 2024 introduced hemp-derived THC beverages, which quickly gained acclaim, winning The High Times Cannabis Cup within a year[168]. - The company reported cash consideration of $5.1 million for acquiring MC Brands, which includes the incredibles brand, and $50.0 million for acquiring VCP, which includes multiple intellectual property rights[170][171]. - RYTHM's hemp-derived beverages are available in eleven U.S. states and Canada, with plans for further expansion into premier on-premises destinations[165]. - The company has entered into distribution agreements to expand its hemp-derived beverage products in domestic markets during the first nine months of 2025[174]. - The Señorita brand offers four flavors of THC beverages, including classic Lime Jalapeño Margarita and Mango Margarita, emphasizing low-sugar and low-calorie options[169]. Financial Performance - Revenue for the three months ended September 30, 2025, was $4.043 million, an increase of $4 million compared to the same period in 2024[196]. - Non-licensing revenue for the three months ended September 30, 2025, was $3.511 million, with $696 thousand attributable to related parties[196]. - Revenue for the nine months ended September 30, 2025, was $6.623 million, an increase of $6.6 million compared to the same period in 2024[197]. - Net loss for the three months ended September 30, 2025, was $10.665 million, compared to a net loss of $18.651 million for the same period in 2024[195]. - Net loss per share attributable to common stockholders for the three months ended September 30, 2025, was $(5.33) compared to $(17.28) for the same period in 2024[195]. - The company reported a net loss of $19.7 million for the nine months ended September 30, 2025, which included $2.5 million related to depreciation and amortization[219]. Costs and Expenses - Cost of goods sold for the three months ended September 30, 2025, was $2.668 million, an increase of $2.6 million compared to the same period in 2024[198]. - Gross profit for the three months ended September 30, 2025, was $1.375 million, representing 34.0% of total revenue[200]. - Selling, general and administrative expenses for the three months ended September 30, 2025, were $10.263 million, an increase of 741% compared to the same period in 2024[202]. - SG&A expenses included $3.1 million attributable to related parties for the three months ended September 30, 2025[202]. - SG&A expenses increased by $17.7 million, or 467%, for the nine months ended September 30, 2025, compared to the same period in 2024[203]. Cash Flow and Financing - Net cash used in operating activities was $20.5 million for the nine months ended September 30, 2025, compared to $6.3 million for the same period in 2024[218]. - Net cash used in investing activities was $55.1 million for the nine months ended September 30, 2025, primarily due to the acquisition of MC Brands and VCP[221]. - Net cash provided by financing activities was $80.0 million for the nine months ended September 30, 2025, resulting from proceeds from May and August 2025 Notes[222]. - As of September 30, 2025, the company had cash and cash equivalents totaling $35.6 million[212]. Business Operations and Strategy - The company exited the Extraction Business on March 30, 2025, which previously provided innovative cultivation and extraction solutions for the cannabis industry[166]. - RYTHM's proprietary Agrify Vertical Farming Units (VFUs) were sold prior to the sale of the Cultivation Business on December 31, 2024, enabling high-quality product production[175]. - RYTHM's co-manufacturing arrangements are designed to ensure continuity of supply and minimize transportation costs, with ongoing efforts to secure additional facilities[172]. - The company recognizes the imprecision in estimating product demand, particularly for new products, which may impact its ability to satisfy market demand[173]. Interest and Liabilities - Interest expense, net was $1.1 million for the three months ended September 30, 2025, compared to $38 thousand for the same period in 2024, reflecting a 2884% increase due to a $50 million principal increase under Convertible Notes[205]. - The change in fair value of warrant liabilities increased by $14.4 million, or 96%, during the three months ended September 30, 2025, compared to the same period in 2024[207]. Accounting and Reporting - Recently issued accounting pronouncements are detailed in Note 1 of the unaudited condensed consolidated financial statements[227]. - New accounting pronouncements not yet adopted are also included in Note 1 of the unaudited condensed consolidated financial statements[228]. - As a "smaller reporting company," the company is not required to provide market risk disclosures[229].

Exhibit 99.1 Fulgent Reports Third Quarter 2025 Financial Results EL MONTE, CA, November 7, 2025 — Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. For the full year 2025, Fulgent now expects: *Cash expenditures may be higher or lower than currently estimated due to a variety of factors an ...